• Users Online: 70
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2019  |  Volume : 1  |  Issue : 4  |  Page : 117-126

Galectin-3 and Fibrosis: Research in the Last 5 Years


Amitabha Medical Clinic and Healing Center, Santa Rosa, California, USA

Correspondence Address:
Dr. Isaac Eliaz
Amitabha Medical Clinic and Healing Center, 398 Tesconi Ct, Santa Rosa, California
USA
Login to access the Email id


DOI: 10.4103/jtccm.jtccm_15_19

Get Permissions

Tissue fibrosis is initially an adaptive response to organ injury, but eventually, parenchymal scarring and subsequent cellular dysfunction and organ failure ensue. Few therapies currently exist for fibrosis, especially those that target fibrogenesis. Galectin-3 (Gal-3) is a member of the lectin family of proteins, is produced predominantly by macrophages, and has essential functions in inflammation and angiogenesis. Gal-3 is activated in fibrotic models and abnormally elevated in fibrotic patients. Gal-3 inhibitors help to ameliorate or prevent fibrosis. For this review, we searched for original articles and reviews published between Jul 1, 2014, and Nov 1, 2019, using the following search terms (or combination of words) in PubMed: “galectin 3”, “fibrosis”, “heart”, “cardiac”, “liver”, “hepatic”, “lung”, “pulmonary”, “kidney”, and “renal”.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed424    
    Printed10    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal